創業集團控股(02221.HK)完成配售5092.2萬股 融資約1029萬港元
格隆匯 7 月 2日丨創業集團控股(02221.HK)發佈公告,配售協議所載配售事項的先決條件已達成,且配售事項已於2020年7月2日按照配售協議的條款及條件完成。公司已根據一般授權按配售價每股配售股份0.202港元向認購人配發及發行合共5092.2萬股配售股份,相當於該公佈日期公司經配售股份擴大後已發行股本約7.56%。
中國北方證券已根據配售協議償付總配售價,配售事項的所得款項總額約為1029萬港元,而所得款項淨額預計約為970萬港元。公司擬將所得款項淨額用作一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.